Literature DB >> 7014638

Sol particle immunoassay (SPIA).

J H Leuvering, P J Thal, M van der Waart, A H Schuurs.   

Abstract

We describe the use of inorganic (metal) colloidal particles as a label for immunoassays. Dose-response curves for human placental lactogen (HPL) and human chorionic gonadotrophin (HCG) were obtained with sandwich immunoassays, using conjugates consisting of antibody-coated colloidal gold or silver particles. Several techniques were used to measure the amount of bound conjugate, viz. colorimetry and carbon rod atomic absorption spectrophotometry (CRAAS). At higher antigen concentrations the results of the assay could be read by the naked eye. Using gold particles as label and CRAAS as detection method, we found a detection limit for a sandwich HPL sol particle immunoassay (SPIA) of 1,4 pmol/l, which was equal to that of an optimalized competitive radioimmunoassay. When using a colorimeter the detection limit for HPL of this SPIA was 5,4 pmol/l, which was superior to that of a corresponding sandwich enzyme-immunoassay (EIA). HPL and HCG were also simultaneously determined, using microtitration plates, coated with a mixture of anti-HPL and anti-HCG, and a mixture of silver particle anti-HPL conjugate and gold particle anti-HCG conjugate. CRAAS was used to measure the bound amount of silver and gold conjugate. This simultaneous assay requires more work in order to obtain better sensitivities.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7014638     DOI: 10.1080/01971528008055777

Source DB:  PubMed          Journal:  J Immunoassay        ISSN: 0197-1522


  16 in total

Review 1.  Biosensors for Detection of Human Placental Pathologies: A Review of Emerging Technologies and Current Trends.

Authors:  Jia Liu; Babak Mosavati; Andrew V Oleinikov; E Du
Journal:  Transl Res       Date:  2019-05-20       Impact factor: 7.012

Review 2.  Point-of-Care Testing for Infectious Diseases: Past, Present, and Future.

Authors:  Thomas R Kozel; Amanda R Burnham-Marusich
Journal:  J Clin Microbiol       Date:  2017-05-24       Impact factor: 5.948

Review 3.  Current Status and Future Direction of Nanomedicine: Focus on Advanced Biological and Medical Applications.

Authors:  Eun-Mi Kim; Hwan-Jeong Jeong
Journal:  Nucl Med Mol Imaging       Date:  2016-08-09

4.  Probing dynamically tunable localized surface plasmon resonances of film-coupled nanoparticles by evanescent wave excitation.

Authors:  Jack J Mock; Ryan T Hill; Yu-Ju Tsai; Ashutosh Chilkoti; David R Smith
Journal:  Nano Lett       Date:  2012-03-23       Impact factor: 11.189

5.  Enhancing nanoparticle-based visible detection by controlling the extent of aggregation.

Authors:  Seokwon Lim; Ok Kyung Koo; Young Sang You; Yeong Eun Lee; Min-Sik Kim; Pahn-Shick Chang; Dong Hyun Kang; Jae-Hyuk Yu; Young Jin Choi; Sundaram Gunasekaran
Journal:  Sci Rep       Date:  2012-06-13       Impact factor: 4.379

6.  Gold nanoparticles in biology and medicine: recent advances and prospects.

Authors:  L A Dykman; N G Khlebtsov
Journal:  Acta Naturae       Date:  2011-04       Impact factor: 1.845

Review 7.  Engineered Gold-Based Nanomaterials: Morphologies and Functionalities in Biomedical Applications. A Mini Review.

Authors:  Iole Venditti
Journal:  Bioengineering (Basel)       Date:  2019-06-10

Review 8.  Analytical and theranostic applications of gold nanoparticles and multifunctional nanocomposites.

Authors:  Nikolai Khlebtsov; Vladimir Bogatyrev; Lev Dykman; Boris Khlebtsov; Sergey Staroverov; Alexander Shirokov; Larisa Matora; Vitaly Khanadeev; Timofey Pylaev; Natalia Tsyganova; Georgy Terentyuk
Journal:  Theranostics       Date:  2013-02-20       Impact factor: 11.556

9.  A minimal fragment of MUC1 mediates growth of cancer cells.

Authors:  Sanjeev Mahanta; Shawn P Fessler; Jaehong Park; Cynthia Bamdad
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

Review 10.  Signal amplification and quantification on lateral flow assays by laser excitation of plasmonic nanomaterials.

Authors:  Haihang Ye; Yaning Liu; Li Zhan; Yilin Liu; Zhenpeng Qin
Journal:  Theranostics       Date:  2020-03-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.